

Subrata Ghosh, MD, AGAF, FCAHS, FRCP (C), FRCPE

Andrzej S. Tarnawski, MD, DSc, PhD

Editors-in-Chief

World Journal of Gastroenterology

Re: WJG-63193

“From A to E – A Critical Review of Viral Hepatitis”

February 28th, 2021.

Dear Editors,

Thank you for the detailed review and insightful comments from you and the reviewers. We appreciate the comments, and we have revised our paper accordingly.

In the following section, we provide detailed answers point-by-point to the reviewers' comments. We are available for discussion and further improvements, if needed.

Response to reviewers:

Reviewer #1

1. Viral hepatitis is still a common clinical disease in the world. A comprehensive understanding of the characteristics of various types of hepatitis is helpful for clinicians to better deal with related clinical problems. The authors provides an overview of viral hepatitis, from epidemiology, viral characteristics to clinical manifestations, and discusses current and future treatments. It is very helpful for clinicians to systematically understand the progress of related disciplines.

R/: Thanks so much for your comments, your words are very appreciated.

Reviewer #2

1. I would like to say that the authours of the manuscript have adapted well and used the new international research results in this traditional Review article. The manuscript is a well organized one, and the new published research practices in the field of viral hepatitis are applied adequately. I want to appreciate the authors also, for covering all critical aspects of

Hepatitis, for example, Epidemiology, Pathophysiology, Immunology and then focusing on new therapeutic options in viral hepatitis, especially in therapeutic vaccines and new drug therapies for HBV. I agree for publishing this manuscript. Thanks for your time and consideration.

R/: Thanks so much for your comments, your words are very appreciated.

Science Editor:

1. The “Author Contributions” section is missing. Please provide the author contributions.

R/: Thanks for your suggestion. We have updated .

2. The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

R/: Thanks for your suggestion. We have included a total of 3 pictures in our manuscript, **all of which are original pictures made by us**, based on published data. We have referenced the studies from which this data was extracted, but the entirety of the graphs included are original.

- Figure 1 was based on the data published in article by Velkov S, Ott JJ, Protzer U, Michler T. The Global Hepatitis B Virus Genotype Distribution Approximated from Available Genotyping Data. *Genes*. 2018 Oct 15;9(10) [PMID: 30326600 DOI: 10.3390/genes9100495. This citation was included – number 41.

- Figure 2 was based on the data published in the following article: World Health Organization. Web Annex B. WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015. In: Global hepatitis report 2017. <https://apps.who.int/iris/bitstream/handle/10665/277005/WHO-CDS-HIV-18.46-eng.pdf>. This citation was included – number 84.

- Figure 3 was based on the data published in the following article: Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology*. 2013 Apr;57(4):1333–42 [PMID: 23172780 DOI: 10.1002/hep.26141]. This citation was included – number 88.

We have included the figures in the submission as PPT files.

3. Please obtain permission for the use of picture(s). If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, “Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. *World J Gastroenterol* 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]”. And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she

will be subject to withdrawal of the article from BPG publications and may even be held liable.

R/: Thanks for your comment. **All pictures included in our study are of our own authorship. No pictures included in our article have been used or published elsewhere.** Hence, there is no need to request permission to include any pictures.

Sincerely,

The Authors